Trial · NCT00829166
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC) | Trastuzumab Emtansine | 53.5 | percentage of participants | ||
| Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC) | Lapatinib + Capecitabine | 61.3 | percentage of participants | ||
| Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint) | Trastuzumab Emtansine | 9.6 | 95% Confidence Interval 8.25 to 10.64 | Months | |
| Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint) | Lapatinib + Capecitabine | 6.4 | 95% Confidence Interval 5.68 to 7.06 | Months | |
| Percentage of Participants Who Died: Second Interim Analysis | Trastuzumab Emtansine | 30.1 | percentage of participants | ||
| Percentage of Participants Who Died: Second Interim Analysis | Lapatinib + Capecitabine | 36.7 | percentage of participants | ||
| Overall Survival: Second Interim Analysis (Co-primary Endpoint) | Trastuzumab Emtansine | 30.9 | 95% Confidence Interval 26.81 to 34.27 | Months | |
| Overall Survival: Second Interim Analysis (Co-primary Endpoint) | Lapatinib + Capecitabine | 25.1 | 95% Confidence Interval 22.74 to 27.96 | Months | |
| Percentage of Participants Who Died: Final Analysis | Trastuzumab Emtansine | 61.2 | percentage of participants | ||
| Percentage of Participants Who Died: Final Analysis | Lapatinib + Capecitabine | 67.1 | percentage of participants | ||
| Overall Survival: Final Analysis | Trastuzumab Emtansine | 29.9 | 95% Confidence Interval 26.32 to 34.10 | Months | |
| Overall Survival: Final Analysis | Lapatinib + Capecitabine | 25.9 | 95% Confidence Interval 22.74 to 28.32 | Months | |
| Percentage of Participants Who Were Alive at Year 1 | Trastuzumab Emtansine | 85.3 | 95% Confidence Interval 82.15 to 88.54 | percentage of participants | |
| Percentage of Participants Who Were Alive at Year 1 | Lapatinib + Capecitabine | 78.9 | 95% Confidence Interval 75.19 to 82.65 | percentage of participants | |
| Percentage of Participants Who Were Alive at Year 2 | Trastuzumab Emtansine | 59.6 | 95% Confidence Interval 55.10 to 64.06 | percentage of participants | |
| Percentage of Participants Who Were Alive at Year 2 | Lapatinib + Capecitabine | 52.4 | 95% Confidence Interval 47.81 to 57.08 | percentage of participants | |
| Percentage of Participants With PD or Death as Assessed by the Investigator | Trastuzumab Emtansine | 58.0 | percentage of participants | ||
| Percentage of Participants With PD or Death as Assessed by the Investigator | Lapatinib + Capecitabine | 67.5 | percentage of participants | ||
| PFS as Assessed by the Investigator | Trastuzumab Emtansine | 9.4 | 95% Confidence Interval 7.49 to 10.78 | Months | |
| PFS as Assessed by the Investigator | Lapatinib + Capecitabine | 5.8 | 95% Confidence Interval 5.59 to 6.93 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00829166/results